Search results for "Hepatitis A Antibodie"

showing 5 items of 5 documents

Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins.

2002

Summary Background The course of viral hepatitis is thought to be affected by genetic host variability and, in particular, by genes of the major histocompatibility locus. Hepatitis A and B vaccination is a useful model to study the effect of host factors on the immune response to viral antigens. We aimed to assess the heritability of the HBsAg (anti-HBs) and anti-hepatitis A virus (anti-HAV) immune response and to estimate the effect of the HLA-DRB1 locus and other genetic loci unlinked to HLA. Methods We did an open prospective study and vaccinated 202 twin pairs with a combined recombinant HBsAg/inactivated hepatitis A vaccine. We measured antibodies to HBsAg and HAV and determined HLA-DR…

AdultMaleHBsAgAdolescentHepatitis A vaccineHuman leukocyte antigenBiologyHepatitis A AntibodiesmedicineHumansHepatitis B VaccinesHepatitis B AntibodiesAgedGeneticsHepatitis B Surface AntigensVaccinationvirus diseasesHepatitis AGeneral MedicineHLA-DR AntigensHeritabilityMiddle Agedmedicine.diseasebiology.organism_classificationdigestive system diseasesRecombinant ProteinsImmunity ActiveHepadnaviridaeImmunologybiology.proteinTwin Studies as TopicFemaleHepatitis A virusAntibodyViral hepatitisHLA-DRB1 ChainsLancet (London, England)
researchProduct

Anti-hepatitis A virus seroprevalence and seroconversion in a cohort of patients with chronic viral hepatitis

2002

Abstract Background. Patients with chronic hepatitis C infected by hepatitis A virus have a substantial risk of fulminant hepatitis or death, while the course of hepatitis A virus is uncomplicated in most subjects with chronic hepatitis B. Aim. To evaluate the prevalence of anti-hepatitis A virus antibodies and the incidence of hepatitis A virus seroconversion in a nationwide sample of 530 patients with chronic hepatitis B and/or hepatitis C infection initially susceptible to this infection after a follow-up of some years. Results. The overall anti-hepatitis A virus prevalence was 85.7%, with no difference between males and females. By the age of 50 years, almost all patients were found to …

AdultMalemedicine.medical_specialtyAdolescentHepatitis C virusmedicine.disease_causeHepatitis A AntibodiesVirusHepatitis B ChronicSeroepidemiologic StudiesInternal medicinemedicineHumansSeroconversionFulminant hepatitisAgedHepatitis B virusHepatologybusiness.industryIncidenceGastroenterologyHepatitis CHepatitis BHepatitis AHepatitis C ChronicMiddle Agedmedicine.diseaseVirologyChronic liver disease; Hepatitis A virus superinfection; Hepatitis B virus; Hepatitis C virus;ItalyHepatitis A AntibodieFemalebusinessViral hepatitisHepatitis A Virus HumanHuman
researchProduct

Exposure to HAV infection in patients with chronic liver disease in Italy, a multicentre study*.

2005

Summary.  We carried out a multicentre study on 2830 patients with chronic liver disease from 79 liver units (25 in northern, 24 in central and 30 in southern Italy) to evaluate naturally acquired immunity against hepatitis A virus (HAV) in relation to age, sex, geographical area of origin and entity of liver disease, and to define the strategy for specific vaccination. Antibody to HAV (anti-HAV) was detected in 1514 (53.5%) of the 2830 patients tested; the prevalence was 50.4% in males and 59.1% in females. Both in central and southern Italy the prevalence of anti-HAV positive subjects increased with increasing age from 43.3 and 44.7%, respectively, in the 0–30-year-old subjects to 80.1 an…

AdultMalemedicine.medical_specialtyCirrhosisAdolescentHepatitis A AntibodiesChronic liver diseaseLiver diseaseSeroepidemiologic StudiesVirologyInternal medicinePrevalencemedicineHumansIn patientChildChronic liver disease HAV infection HAV vaccination HBV chronic infection HCV chronic infection Total anti-HAVAgedAged 80 and overHigh prevalenceHepatologybiologybusiness.industryLiver DiseasesInfantHepatitis AHepatitis AMiddle Agedmedicine.diseaseVaccinationCross-Sectional StudiesInfectious DiseasesItalyChild PreschoolImmunoglobulin GChronic DiseaseImmunologybiology.proteinFemaleAntibodybusinessHepatitis A Virus Human
researchProduct

Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases.

2007

Hepatitis A virus (HAV) or hepatitis B virus (HBV) superinfection is associated with an increased mortality in patients with chronic liver diseases (CLD). Despite official recommendations, it was reported that the vaccination rate against HAV is low in patients with chronic hepatitis C infection. To evaluate the situation in patients with autoimmune liver diseases, we conducted a retrospective cohort study.Susceptibility to HAV and HBV infections, course of HAV and HBV infections, vaccination rates against HAV and HBV, and efficacy of hepatitis A/B vaccines were evaluated by antibody testing in 225 patients with autoimmune liver diseases during 1,677 person-years.Susceptibility to HAV/HBV i…

AdultMalemedicine.medical_specialtyHepatitis B virusvirusesHepatitis A AntibodiesImmunopathologyGermanyEpidemiologymedicineHumansHepatitis B VaccinesHepatitis B AntibodiesRetrospective StudiesAutoimmune diseaseHepatitisHepatitis A VaccinesHepatitis B Surface AntigensHepatologybiologybusiness.industryIncidence (epidemiology)IncidencefungiVaccinationGastroenterologyvirus diseasesbiochemical phenomena metabolism and nutritionHepatitis AMiddle Agedmedicine.diseaseHepatitis BPrognosisdigestive system diseasesVaccinationHepatitis AutoimmuneAntibodies AntinuclearImmunologyDNA Viralbiology.proteinFemaleViral diseaseDisease SusceptibilityHepatitis A virusAntibodybusinessFollow-Up StudiesThe American journal of gastroenterology
researchProduct

Antibody persistence and immune memory elicited by combined hepatitis A and B vaccination in older adults.

2007

Response to hepatitis A and B vaccines has been reported to decline with age. This open, prospective, single-site study examined the long-term response to the combined hepatitis A/B vaccine Twinrix in 98 primary responders aged 45-67 years. Levels of antibody against hepatitis A virus (HAV) and hepatitis B surface antigen (HBs) were tested 30 months after initial vaccination. At this stage, all participants remained seropositive for anti-HAV and 70% for anti-HBs. A booster vaccination was offered to those who had responded to the first vaccination but then lost protective levels of anti-HBs. An anamnestic response was observed in all cases.

MaleTwinrixHepatitis A AntibodiesCohort StudiesMedicineHumansHepatitis B VaccinesProspective StudiesVaccines CombinedHepatitis B AntibodiesProspective cohort studyAgedHepatitis A VaccinesHepatitis B Surface AntigensGeneral VeterinaryGeneral Immunology and Microbiologybiologybusiness.industryPublic Health Environmental and Occupational Healthvirus diseasesHepatitis AMiddle Agedmedicine.diseaseVirologydigestive system diseasesVaccinationClinical trialInfectious DiseasesImmunologyAntibody Formationbiology.proteinMolecular MedicineFemaleViral diseaseAntibodybusinessImmunologic MemoryCohort studyVaccine
researchProduct